Gilead pays $4.3B for CymaBay, the biotech that never gave up on liver disease med

Gilead pays $4.3B for CymaBay, the biotech that never gave up on liver disease med

Submitted by admin on February 12, 2024 - 11:53am
Source: 
Fierce Biotech
News Tags: 
Gilead Sciences
CymaBay Therapeutics
M&A
liver disease
seladelpar
primary biliary cholangitis
Headline: 
Gilead pays $4.3B for CymaBay, the biotech that never gave up on liver disease med
snippet: 

Gilead Sciences is bolstering its liver disease portfolio with the $4.3 billion acquisition of CymaBay Therapeutics, specifically for the primary biliary cholangitis (PBC) med seladelpar.

Do Not Allow Advertisers to Use My Personal information